- Conditions
- Heart Diseases, Metabolism, Inborn Errors
- Interventions
- SCH-58235, Ezetimibe
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,110
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Congenital Heart Defect
- Interventions
- XFM guidance
- Procedure
- Lead sponsor
- Joshua Kanter
- Other
- Eligibility
- Not listed
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Hypogammaglobulinemia, Congenital Heart Disease
- Interventions
- IVIG, Placebo
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Long QT Syndrome
- Interventions
- GS-6615
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Hypoplastic Left Heart Syndrome, Tetralogy of Fallot
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Day to 1 Year
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cardiopulmonary Bypass, Congenital Heart Defects
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cardiovascular Diseases
- Interventions
- Energy drink, Placebo drink
- Other
- Lead sponsor
- University of the Pacific
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Stockton, California
- Conditions
- Patient-Reported Outcome Measures (PROMs), Pragmatic Trial, Adolescent Congenital Heart Disease, Resiliency-building Intervention, Resilience, Psychological, Telemedicine-Based Education
- Interventions
- Telemedicine-based resiliency-building intervention
- Behavioral
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 14
- States / cities
- Stanford, California • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Congenital Heart Block, Neonatal Lupus, Autoantibody-associated Heart Block
- Interventions
- intravenous immune globulin (IVIG)
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Livingston, New Jersey • New York, New York
- Conditions
- Marfan Syndrome
- Interventions
- Losartan Potassium, Atenolol
- Drug
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 6 Months to 25 Years
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 18 more
- Conditions
- Williams Syndrome, Supravalvular Aortic Stenosis, Cardiovascular Disease
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 3 Years to 85 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2024
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • St Louis, Missouri
- Conditions
- Lumbar Spinal Stenosis, Carpal Tunnel Syndrome (CTS), Cardiac Amyloidosis
- Interventions
- 124I-evuzamitide
- Drug
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Gingival Recession, Lack of Keratinized Gingiva (Disorder)
- Interventions
- progenitor potential of Gingival Mesenchymal cells
- Diagnostic Test
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Congenital Heart Disease With Fontan Circulation
- Interventions
- macitentan 10 mg
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Spokane, Washington
- Conditions
- Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2), Mitochondrial Trifunctional Protein Deficiency, Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency, Glycogen Storage Disorders, Pyruvate Carboxylase Deficiency Disease, ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY of, Barth Syndrome
- Interventions
- triheptanoin
- Drug
- Lead sponsor
- Jerry Vockley, MD, PhD
- Other
- Eligibility
- 1 Month and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hypoplastic Left Heart Syndrome
- Interventions
- autologous cell-based delivery
- Biological
- Lead sponsor
- Timothy J Nelson, MD, PhD
- Other
- Eligibility
- Up to 18 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Minneapolis, Minnesota + 3 more
- Conditions
- Hypoplastic Left Heart Syndrome
- Interventions
- Fetal Aortic Valvuloplasty Procedure, Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter, Trek RX and Mini Trek RX Coronary Dilatation Catheter
- Procedure · Device
- Lead sponsor
- Mauro H. Schenone
- Other
- Eligibility
- Up to 45 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2036
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Congenital Heart Disease
- Interventions
- Dexmedetomidine
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 6 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Congenital Heart Disease
- Interventions
- continuous infusion, as needed dosing, Acetaminophen, ketorolac
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 3 Months to 4 Months
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Oak Lawn, Illinois
- Conditions
- Hypoplastic Left Heart Syndrome (HLHS)
- Interventions
- Collaborative Learning Network
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 15 Months
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Cardiovascular Diseases, Hypertension, Heart Failure, Atrial Fibrillation, Metabolic Syndrome, Genetic Disease
- Interventions
- Digital Health Device Diagnostics
- Diagnostic Test
- Lead sponsor
- Scripps Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Myocardial Bridging
- Interventions
- Nebivolol, Diltiazem, Placebo
- Drug · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Pulmonary Regurgitation After Repair of Tetralogy of Fallot
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Tetrology of Fallot
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts